223 related articles for article (PubMed ID: 22404139)
1. HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.
Agniswamy J; Shen CH; Aniana A; Sayer JM; Louis JM; Weber IT
Biochemistry; 2012 Apr; 51(13):2819-28. PubMed ID: 22404139
[TBL] [Abstract][Full Text] [Related]
2. Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease.
Louis JM; Tözsér J; Roche J; Matúz K; Aniana A; Sayer JM
Biochemistry; 2013 Oct; 52(43):7678-88. PubMed ID: 24079831
[TBL] [Abstract][Full Text] [Related]
3. Structural Studies of a Rationally Selected Multi-Drug Resistant HIV-1 Protease Reveal Synergistic Effect of Distal Mutations on Flap Dynamics.
Agniswamy J; Louis JM; Roche J; Harrison RW; Weber IT
PLoS One; 2016; 11(12):e0168616. PubMed ID: 27992544
[TBL] [Abstract][Full Text] [Related]
4. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
Liu F; Kovalevsky AY; Tie Y; Ghosh AK; Harrison RW; Weber IT
J Mol Biol; 2008 Aug; 381(1):102-15. PubMed ID: 18597780
[TBL] [Abstract][Full Text] [Related]
5. Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.
Agniswamy J; Shen CH; Wang YF; Ghosh AK; Rao KV; Xu CX; Sayer JM; Louis JM; Weber IT
J Med Chem; 2013 May; 56(10):4017-27. PubMed ID: 23590295
[TBL] [Abstract][Full Text] [Related]
6. Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights.
Chetty S; Bhakat S; Martin AJ; Soliman ME
J Biomol Struct Dyn; 2016; 34(1):135-51. PubMed ID: 25671669
[TBL] [Abstract][Full Text] [Related]
7. Structures of darunavir-resistant HIV-1 protease mutant reveal atypical binding of darunavir to wide open flaps.
Zhang Y; Chang YC; Louis JM; Wang YF; Harrison RW; Weber IT
ACS Chem Biol; 2014 Jun; 9(6):1351-8. PubMed ID: 24738918
[TBL] [Abstract][Full Text] [Related]
8. Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
Agniswamy J; Louis JM; Shen CH; Yashchuk S; Ghosh AK; Weber IT
J Med Chem; 2015 Jun; 58(12):5088-95. PubMed ID: 26010498
[TBL] [Abstract][Full Text] [Related]
9. Conformational variation of an extreme drug resistant mutant of HIV protease.
Shen CH; Chang YC; Agniswamy J; Harrison RW; Weber IT
J Mol Graph Model; 2015 Nov; 62():87-96. PubMed ID: 26397743
[TBL] [Abstract][Full Text] [Related]
10. Highly drug-resistant HIV-1 protease reveals decreased intra-subunit interactions due to clusters of mutations.
Kneller DW; Agniswamy J; Harrison RW; Weber IT
FEBS J; 2020 Aug; 287(15):3235-3254. PubMed ID: 31920003
[TBL] [Abstract][Full Text] [Related]
11. Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20.
Kneller DW; Agniswamy J; Ghosh AK; Weber IT
Biochem Biophys Res Commun; 2019 Oct; 519(1):61-66. PubMed ID: 31474336
[TBL] [Abstract][Full Text] [Related]
12. Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency.
Goldfarb NE; Ohanessian M; Biswas S; McGee TD; Mahon BP; Ostrov DA; Garcia J; Tang Y; McKenna R; Roitberg A; Dunn BM
Biochemistry; 2015 Jan; 54(2):422-33. PubMed ID: 25513833
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT
FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957
[TBL] [Abstract][Full Text] [Related]
14. Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme.
Park JH; Sayer JM; Aniana A; Yu X; Weber IT; Harrison RW; Louis JM
Biochemistry; 2016 Apr; 55(16):2390-400. PubMed ID: 27039930
[TBL] [Abstract][Full Text] [Related]
15. Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
Shen CH; Wang YF; Kovalevsky AY; Harrison RW; Weber IT
FEBS J; 2010 Sep; 277(18):3699-714. PubMed ID: 20695887
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 protease with 10 lopinavir and darunavir resistance mutations exhibits altered inhibition, structural rearrangements and extreme dynamics.
Wong-Sam A; Wang YF; Kneller DW; Kovalevsky AY; Ghosh AK; Harrison RW; Weber IT
J Mol Graph Model; 2022 Dec; 117():108315. PubMed ID: 36108568
[TBL] [Abstract][Full Text] [Related]
17. Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.
Tie Y; Kovalevsky AY; Boross P; Wang YF; Ghosh AK; Tozser J; Harrison RW; Weber IT
Proteins; 2007 Apr; 67(1):232-42. PubMed ID: 17243183
[TBL] [Abstract][Full Text] [Related]
18. Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.
Tie Y; Wang YF; Boross PI; Chiu TY; Ghosh AK; Tozser J; Louis JM; Harrison RW; Weber IT
Protein Sci; 2012 Mar; 21(3):339-50. PubMed ID: 22238126
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
Logsdon BC; Vickrey JF; Martin P; Proteasa G; Koepke JI; Terlecky SR; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
J Virol; 2004 Mar; 78(6):3123-32. PubMed ID: 14990731
[TBL] [Abstract][Full Text] [Related]
20. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
Tzoupis H; Leonis G; Avramopoulos A; Mavromoustakos T; Papadopoulos MG
J Phys Chem B; 2014 Aug; 118(32):9538-52. PubMed ID: 25036111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]